Role of cholecystokinin in postprandial and vagally stimulated duodenal and gallbladder motility in dogs.
This study was designed to determine the role of cholecystokinin (CCK) in postprandial motility pattern of the duodenum and gallbladder (GB) in conscious dogs provided with chronic duodenal electrodes for recording of myoelectric activity and GB fistulas for measurement of intraluminal pressure and volume of GB and to calculate the GB motility index (MI) and GB emptying rate. During naturally occurring activity front (phase III MMC) in the duodenum there was significant increase in the MI of GB accompanied by about 20-30% reduction in the GB volume. These changes in duodenal and GB motility pattern could be duplicated by i.v. motilin. Feeding abolished the appearance of spontaneous activity front in the duodenum and greatly increased motility of GB while reducing its volume. Administration of CCK receptor antagonists in fed dogs failed to affect the motility changes induced by meal in the duodenum but abolished these of the GB. Vagal cholinergic stimulation with insulin, 2DG or urecholine caused similar effects to that induced by food i.e. increased duodenal spike activity, abolished phase III of the MMC, decreased GB volume and increased GB motility. Pretreatment with CCK antagonists did not affect significantly duodenal spike activity or GB motility but significantly increased the GB volume. Atropine 125 micrograms/kg) blocked almost completely spontaneous activity front in the duodenum and accompanying alterations in the motility and volume of GB. We conclude that CCK contributes to the MMC related alterations in the GB motor activity and is essential in cholinergic stimulation induced of the GB emptying but not in vagally induced duodenal and GB motility.
Thor
P
P
Institute of Physiology, University Medical School, Krakow, Poland.
Laskiewcz
J
J
Maczka
M
M
Konturek
S J
SJ
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D001626:Bethanechol Compounds / Q000494:pharmacology; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D003847:Deoxyglucose / Q000494:pharmacology; D020109:Devazepide; D004285:Dogs; D004386:Duodenum / Q000502:physiology*; D004435:Eating / Q000502:physiology*; D004558:Electric Stimulation; D005704:Gallbladder / Q000502:physiology*; D007328:Insulin / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000187:drug effects; D013268:Stimulation, Chemical; D014630:Vagus Nerve / Q000502:physiology*
D001570:Benzodiazepinones; D001626:Bethanechol Compounds; D007328:Insulin; D011949:Receptors, Cholecystokinin; D002766:Cholecystokinin; D003847:Deoxyglucose; D020109:Devazepide